Literature DB >> 32111777

Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes.

Calogero Cipolla1, Maria Rosaria Valerio2, Nello Grassi2, Sergio Calamia2, Stefania Latteri2, Mario Latteri2, Giuseppa Graceffa2, Salvatore Vieni2.   

Abstract

BACKGROUND/AIM: Recent years have seen a considerable shift to a more conservative management of the axilla in patients with positive axillary sentinel lymph nodes. The aim of this study was to determine whether some breast cancer patients with a preoperative ultrasound-guided needle aspiration biopsy proven positive node could potentially be spared an axillary lymph node dissection according to the ACOSOG Z0011 trial criteria. PATIENTS AND METHODS: A retrospective review was performed involving 623 breast cancer patients who underwent axillary lymph node dissection after either ultrasound-guided needle aspiration biopsy proven positive node or sentinel lymph node biopsy.
RESULTS: Patients with fine needle aspiration biopsy-proven positive node had worse prognosis and a higher nodal burden (6.7 vs 1.9 nodes, p<0.001), compared to those with positive sentinel lymph nodes.
CONCLUSION: Patients with an ultrasound guided needle aspiration biopsy proven positive node are more likely to have tumor with more aggressive pathological characteristics and a higher nodal burden than those with a positive sentinel lymph node biopsy. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; axillary nodal burden; sentinel lymph node biopsy

Year:  2020        PMID: 32111777     DOI: 10.21873/invivo.11831

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.

Authors:  Linda Ye; Dennis Rünger; Stephanie A Angarita; Joseph Hadaya; Jennifer L Baker; Minna K Lee; Carlie K Thompson; Deanna J Attai; Maggie L DiNome
Journal:  Breast Cancer Res Treat       Date:  2022-04-07       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.